NCT01016977View on ClinicalTrials.gov

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Acne Vulgaris
Interventions
DRUG

Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene

Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene

DRUG

clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene

clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY

NCT01016977 - A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris | Biotech Hunter | Biotech Hunter